```
=> d his ful

     (FILE 'HOME' ENTERED AT 15:51:45 ON 15 SEP 2005)

     FILE 'REGISTRY' ENTERED AT 15:51:51 ON 15 SEP 2005
L5              STR
L6            50 SEA SSS SAM L5
L7          1280 SEA SSS FUL L5
L8              STR
L9            52 SEA SUB=L7 SSS FUL L8

     FILE 'HCAPLUS' ENTERED AT 15:55:26 ON 15 SEP 2005
L10           10 SEA ABB=ON  PLU=ON  L9
                 D STAT QUE L10
                 D IBIB ABS HITSTR L10 1-10


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   14 SEP 2005  HIGHEST RN 863180-19-2
     DICTIONARY FILE UPDATES:  14 SEP 2005  HIGHEST RN 863180-19-2

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMITS
     for details.

     Experimental and calculated property data are now available. For more
     information enter HELP PROP at an arrow prompt in the file or refer
     to the file summary sheet on the web at:
     http://www.cas.org/ONLINE/DBSS/registryss.html

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     the American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
```

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Sep 2005 VOL 143 ISS 12
FILE LAST UPDATED: 14 Sep 2005 (20050914/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:55:26 ON 15 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Sep 2005 VOL 143 ISS 12
FILE LAST UPDATED: 14 Sep 2005 (20050914/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
=>

=> d stat que l10
L5 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L7 1280 SEA FILE=REGISTRY SSS FUL L5
L8 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE
L9 52 SEA FILE=REGISTRY SUB=L7 SSS FUL L8
L10 10 SEA FILE=HCAPLUS ABB=ON PLU=ON L9

=>

=>

=> d ibib abs hitstr l10 1-10

L10 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:612019 HCAPLUS
DOCUMENT NUMBER: 143:92536
TITLE: Preparation of 2,4-diaminothiazole derivatives as plant growth regulators
INVENTOR(S): Bastiaans, Henricus M. M.; Donn, Guenter; Knittel, Nathalie; Martelletti, Arianna; Rees, Richard; Schwall, Michael; Whitford, Ryan
PATENT ASSIGNEE(S): Bayer Cropscience G.m.b.H., Germany
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063022	A1	20050714	WO 2004-EP14262	20041215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1550372	A1	20050706	EP 2003-29844	20031224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: EP 2003-29844 A 20031224
EP 2004-11253 A 20040512

GI



AB The 2,4-diaminothiazole derivs. I [E = (un)substituted alkyl, alkenyl, alkynyl, furfuryl, isoxazolyl, etc.; W =, O, NOH. etc.; Q = (un)substituted cycloalkyl, cycloalkylalkyl, aryl, etc.] are prepared as plant growth regulators.

IT **856007-91-5P**
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation as plant growth regulator)

RN 856007-91-5 HCAPLUS

CN Benzoic acid, 4-[[4-amino-5-[4-(difluoromethoxy)benzoyl]-2-thiazolyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:582483 HCAPLUS
DOCUMENT NUMBER: 143:73303
TITLE: Preparation of 2,4-diaminothiazole derivatives as plant growth regulators
INVENTOR(S): Bastiaans, Henricus M. M.; Donn, Guenter; Knittel, Nathalie; Martelletti, Arianna; Rees, Richard; Schwall, Michael; Whitford, Ryan
PATENT ASSIGNEE(S): Bayer CropScience G.m.b.H., Germany
SOURCE: Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1550372	A1	20050706	EP 2003-29844	20031224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
WO 2005063022	A1	20050714	WO 2004-EP14262	20041215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2003-29844 A 20031224
EP 2004-11253 A 20040512

GI



I

AB The 2,4-diamino-5-substituted-thiazole derivs. I [E = alkyl, alkenyl, alkynyl, alkoxycarbonyl, Ph, pyridinyl, etc.; W = O, NOH, etc.; Q = (un)substituted cycloalkyl, cycloalkylalkyl, etc.] are prepared as plant growth regulators.

IT **856007-91-5P**
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation as plant growth regulator)

RN 856007-91-5 HCAPLUS

CN Benzoic acid, 4-[[4-amino-5-[4-(difluoromethoxy)benzoyl]-2-thiazolyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:140809 HCAPLUS
DOCUMENT NUMBER: 142:240423
TITLE: A preparation of antiproliferative 2-(heteroaryl)aminothiazole derivatives
INVENTOR(S): Chong, Wesley Kwan Mung; Duvadie, Rohit Kumar; Li, Lin; Yang, Yi
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 37 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005038078	A1	20050217	US 2003-639219	20030811
US 2005176773	A1	20050811	US 2005-105939	20050413
PRIORITY APPLN. INFO.:			US 2003-639219	A3 20030811
OTHER SOURCE(S):	MARPAT 142:240423			

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of 2-(heteroaryl)aminothiazole derivs. of formula I [wherein: R1 is H, alk(en/yn)yl, alkylamino, aryl, or cycloalkyl; R2 and R5 are independently selected from H, halogen, alkyl, NH2, SMe, or NO2, etc.; R3 and R4 are independently selected from H, halogen, methoxy, or alkyl], useful as antiproliferative agents. For instance, nicotinamide derivative II (inhibition of HCT-116 cell growth: IC50 = 0.007 μM) was prepared via amidation of nicotinic acid derivative III by (N-methyl-pyrrolidin-2S-yl)methylamine with a yield of 60%.

IT **657410-74-7P 657410-75-8P 657410-83-8P**
657410-84-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of antiproliferative 2-(heteroaryl)aminothiazole derivs.)

RN 657410-74-7 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 657410-75-8 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 657410-83-8 HCAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 657410-84-9 HCAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



L10 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:99173 HCAPLUS
DOCUMENT NUMBER: 142:197575
TITLE: Process for preparation of chiral 1,2-diaminopropanes and thiazole compounds containing them.
INVENTOR(S): Kucera, David John; Yvon, Brigitte Leigh

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005026966	A1	20050203	US 2003-631358	20030730
PRIORITY APPLN. INFO.:			US 2003-631358	20030730

OTHER SOURCE(S): CASREACT 142:197575; MARPAT 142:197575
GI



AB Title compds. [I; R1-R3 = H, (substituted) alkyl, heteroalkyl, (CR13R14)tX; t = 1-5; X = aryl, cycloalkyl, heterocyclyl; R13, R14 = H, alkyl, heteroalkyl], were prepared by treatment of amino acid derivs. (II) with R2R3NH (R1-R3 as above) to give the corresponding amides followed by N-deprotection, reduction, and conversion to the tosylate salts. I are intermediates in preparation of thiazole derivs. (III; R1-R3 as above; R4, R5 = H, halo, alkyl, OMe, OH, NH2, NHMe, NMe2, NO2, SH, SMe, SOMe, SO2Me, PMe2, PO3H2; R6, R7 = H, halo, MeO, alkyl; X = C, N). Thus, Z-D-Ala-OH and HOBt.H2O in MeCN at -3° were treated with DCC in MeCN and then with Me2NH.HCl and diisopropylethylamine followed by stirring at 0° for 1.5 h, warming to room temperature, and stirring overnight to give 79% N-benzyloxycarbonyl-D-alanine dimethylamide. The latter was hydrogenolyzed in EtOH over Pd/C at 45 psi H2 to give 83% D-alanine dimethylamide. This was refluxed 17 h with LiAlH4 in THF followed by salification with p-TsOH to give 69.5% (R)-1-dimethylaminoprop-2-ylamine. bistosylate.

IT **486413-80-3P 486413-81-4P 657410-74-7P 657410-75-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for preparation of chiral diaminopropanes and thiazole compds. containing them)

RN 486413-80-3 HCAPLUS

CN Benzoic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 486413-81-4 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



RN 657410-74-7 HCAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 657410-75-8 HCAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L10 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:718536 HCAPLUS
DOCUMENT NUMBER: 141:243546
TITLE: Preparation of N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
INVENTOR(S): Alegria, Larry Andrew; Chong, Wesley Kwan Mung; Chu, Shaosong; Duvadie, Rohit Kumar; Li, Lin; Romines, William Henry, III; Yang, Yi
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 307 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074283	A1	20040902	WO 2004-IB433	20040209
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005101595	A1	20050512	US 2004-783887	20040220
PRIORITY APPLN. INFO.:			US 2003-448843P P	20030221

OTHER SOURCE(S): MARPAT 141:243546
GI



I



II

AB The title aminothiazole compds. with N-containing cycloalkyl at the 2-amino position [I; N-containing heterocyclyl = (un)substituted N-containing 3-10 membered heterocyclyl; R1 = H, alkyl, alkenyl, alkoxy, etc.; R2 = (un)substituted alkyl, cycloalkyl, alkoxy, aryl, 4-10 membered heterocyclyl] and their pharmaceutically acceptable prodrugs or salts which modulate and/or inhibit the cell proliferation and activity of protein kinases, were prepared Thus, reacting [4-amino-2-(piperidin-4-ylamino)thiazol-5-yl](2,6-difluorophenyl)methanone (preparation given) with 1-methylpiperidine-4-carboxylic acid afforded 65% II which showed Ki of 0.46 μM against CDK2, Ki of 0.13 μM against CDK4, and IC50 of >5 μM in HCT-116 assay for cell growth inhibition. Biol. data were given for over 1100 compds. I. The pharmaceutical compns. comprising the compound I are claimed.

IT **750573-74-1P 750573-94-5P 750574-07-3P**
750577-85-6P 750577-86-7P 750577-87-8P
750578-55-3P 750578-56-4P 750578-57-5P
750578-58-6P 750578-59-7P 750579-36-3P
750579-38-5P 750579-39-6P 750579-40-9P
750579-41-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-heterocyclyl-substituted amino-thiazole derivs. as protein kinase inhibitors)

RN 750573-74-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 750573-94-5 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)



RN 750574-07-3 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)



RN 750577-85-6 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, phenyl ester (9CI) (CA INDEX NAME)



RN 750577-86-7 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 750577-87-8 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, 2-ethylhexyl ester (9CI) (CA INDEX NAME)



RN 750578-55-3 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 750578-56-4 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)



RN 750578-57-5 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, (1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 750578-58-6 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)



RN 750578-59-7 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, 4-(methoxycarbonyl)phenyl ester (9CI) (CA INDEX NAME)



RN 750579-36-3 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 750579-38-5 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 750579-39-6 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, (1S,2R,5S)-5-methyl-2-(1-methylethyl)cyclohexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 750579-40-9 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, cyclopentyl ester (9CI) (CA INDEX NAME)



RN 750579-41-0 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)



IT **750573-78-5P 750573-80-9P 750573-82-1P**
750573-85-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-heterocyclyl-substituted amino-thiazole derivs. as protein kinase inhibitors)
RN 750573-78-5 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 750573-80-9 HCAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 750573-82-1 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 750573-85-4 HCAPLUS
CN 1-Azetidinecarboxylic acid, 3-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:143146 HCAPLUS
DOCUMENT NUMBER: 140:181441
TITLE: Preparation of antiproliferative 2-(pyridylamino)thiazole compounds
INVENTOR(S): Chong, Wesley Kwan Mung; Duvadie, Rohit Kumar; Li, Lin; Yang, Yi
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014904	A1	20040219	WO 2003-IB3181	20030729

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-402408P P 20020809
OTHER SOURCE(S): MARPAT 140:181441
GI



I



II

AB Thiazole derivs. of formula I [R1 = H, alkenyl, alkylamino, aryl, heteroaryl, cycloalkyl, etc.; R2, R5 = H, halo, alkyl, OMe, OH, amino, SH, SMe, etc.; R3, R4 = H, halo, OMe, alkyl] are prepared The compds. and pharmaceutical compns. containing them may be used in inhibiting and/or modulating protein kinases, in treating or preventing diseases associated with protein kinases, and/or in treating or preventing cellular proliferative diseases. Thus, II was prepared, and had IC50 and IC90 of 0.0026 and 0.0057 μM resp. against HCT-116 cells.

IT **657410-74-7P 657410-75-8P 657410-83-8P**
657410-84-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of antiproliferative (pyridylamino)thiazole compds.)

RN 657410-74-7 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 657410-75-8 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 657410-83-8 HCAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 657410-84-9 HCAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:117812 HCAPLUS
DOCUMENT NUMBER: 138:187762
TITLE: Preparation of novel 2,4-diaminothiazoles as glycogen synthase kinase-3 (GSK-3) inhibitors

INVENTOR(S): Bowler, Andrew Neil; Hansen, Bo Falck
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003011843	A1	20030213	WO 2002-DK508		20020722
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2455753	AA	20030213	CA 2002-2455753		20020722
EP 1417188	A1	20040512	EP 2002-750845		20020722
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002011626	A	20040824	BR 2002-11626		20020722
CN 1547574	A	20041117	CN 2002-816635		20020722
JP 2004538315	T2	20041224	JP 2003-517035		20020722
ZA 2004000733	A	20040824	ZA 2004-733		20040129
US 2004210063	A1	20041021	US 2004-770705		20040203
NO 2004000913	A	20040401	NO 2004-913		20040302
PRIORITY APPLN. INFO.:			DK 2001-1175	A	20010803
			US 2001-309953P	P	20010803
			WO 2002-DK508	W	20020722

OTHER SOURCE(S): MARPAT 138:187762
GI



I



II

AB The title compds. I [A = a bond, alkylene; NR1R2 = (un)substituted 5-7

membered non-aromatic ring, which may contain a double bond and addnl. N atom; or R1 = H, alkyl, arylalkyl, etc. and R2 and R3 are connected to form , together with A and the N atom and C atom, resp., to which they are attached, a 5-7 membered non-aromatic ring; or R1, R2 = H, CO2alkyl, alkyl, etc.; R3 = H; B = a bond, CO, SO, SO2; D = OH, halo, CN, etc.] which inhibit GSK-3 (glycogen synthase kinase-3) and therefore may be useful for the treatment of disorders, syndromes, diseases and conditions, wherein an inhibition of GSK-3 (glycogen synthase kinase-3) is beneficial, especially IGT (impaired glucose tolerance), type 1 diabetes, type 2 diabetes, obesity, Alzheimer's disease and bipolar disorder, were prepared and formulated. Thus, reacting 1-(3-benzyloxyphenyl)-2-bromoethanone with N-Boc-isothiocyanatopropylamine afforded II which showed IC50 of < 1 μM against GSK-3.

IT **496954-38-2P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of novel 2,4-diaminothiazoles as glycogen synthase kinase-3 (GSK-3) inhibitors)

RN 496954-38-2 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-amino-5-[3-(phenylmethoxy)benzoyl]-2-thiazolyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:42245 HCAPLUS

DOCUMENT NUMBER: 138:106689

TITLE: Preparation of thiazolylamino benzamide derivatives as modulators of cell proliferation and inhibitors of protein kinases

INVENTOR(S): Chu, Shao Song; Alegria, Larry Andrew; Bleckman, Ted Michael; Chong, Wesley K. M.; Duvadie, Rohit K.; Li, Lin; Reich, Siegfried H.; Romines, William H.; Wallace, Michael B.; Yang, Yi

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004467	A2	20030116	WO 2002-US21280	20020705

WO 2003004467 A3 20040506
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2452609	AA	20030116	CA 2002-2452609		20020705
US 2003225147	A1	20031204	US 2002-190219		20020705
US 6720346	B2	20040413			
EP 1438046	A2	20040721	EP 2002-782499		20020705
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
JP 2005521631	T2	20050721	JP 2003-510635		20020705
PRIORITY APPLN. INFO.:			US 2001-303679P	P	20010706
			US 2001-305274P	P	20010713
			WO 2002-US21280	W	20020705

OTHER SOURCE(S): MARPAT 138:106689

GI



I

AB Aminothiazole compds. with mono-/di-substituted benzamides (shown as I; variables described below; e.g. 4-[[4-amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-N-(2-morpholin-4-ylethyl)benzamide), and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of said metabolites are described. These agents modulate and/or inhibit the cell proliferation and activity of protein kinases and are useful as pharmaceuticals for treating malignancies and other disorders. Inhibitory activities towards three cyclin complexes of protein kinases, phosphorylated FGF receptor and/or LCK tyrosine kinase and/or cytotoxicity towards the HCT-116 cancer cell line are reported for hundreds of I, many of which were prepared combinatorially. For I: R1 and R2 are each independently H, or an alkyl, alkenyl, alkynyl, heteroalkyl, alkoxy, aminoalkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group unsubstituted or substituted with ≥1 substituents listed in the claims, or R1 or R2, together with the N-C(O) and two adjacent C atoms of the Ph ring of I, forms a 5- or 6-membered ring structure fused to the Ph ring of I and unsubstituted or substituted with ≥1 substituents listed in the claims, or R1 and R2, taken together with the N atom to which they are bonded, form a monocyclic or fused or nonfused polycyclic structure which may contain 1-3 addnl. heteroatoms, the structure being unsubstituted or substituted with ≥1 substituents listed in the claims. R3 is an aryl, heteroaryl, alkyl, or cycloalkyl group, unsubstituted or substituted with ≥1 substituents listed in the claims. Y is H, alkyl, heteroalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, cycloalkyl, heterocycloalkyl, -NO2, -NH2, -N-OH,

N-ORc, -CN, -(CH2)z-CN (z is 0-4), halogen, -OH, -O-Ra-O-, -ORb, -CO-R, -O-CO-Rc, -CO-ORc, -O-CO-OR, -O-OR, =O, =S, -NRdRe, -CO-NRdRe, -O-CO-NRdRe, -NRc-CO-Re, -NR-CO-OR, -CO-NRc-CO-Rd, -O-SO2-Re, -O-SO-R, -O-S-Re, -S-CO-Rc, -SO-CO-ORc, -SO-CO-OR, -O-SO3, -NRc-SRd, -NRc-SO-Rd, NRc-SO2-Rd, -CO-SRc, -CO-SO-Re, -CO-OSO2-Rc, -CS-Rc, -CSO-R, -CSO2-R,, -NRc-CS-Rd, -O-CS-Re, -O-CSO-Rc, -O-SO2-Re, -OS2-NRdRe, -SO-NRdRe, -S-NRdRe, -NRd-CSO2-Rd, - NRc-CSO-Rd, -NRc-CS-Rd, -SH, -S-Rb, and -PO2-ORc (Ra, etc. defined in claims). Although the methods of preparation are not claimed, .apprx.80 example prepns. of I are included and directions are given for combinatorial preparation of 396 I.

IT **486415-22-9P**, 4-[[4-Amino-5-(2-methylsulfonylbenzoyl)thiazol-2-yl]amino]benzoic Acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

RN 486415-22-9 HCAPLUS

CN Benzoic acid, 4-[[4-amino-5-[2-(methylsulfonyl)benzoyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



IT **486413-81-4P**, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]benzoic Acid
RL: CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

RN 486413-81-4 HCAPLUS

CN Benzoic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



IT **223786-78-5P**, 4-[[4-Amino-5-(2,6-dichlorobenzoyl)thiazol-2-yl]amino]benzoic acid **486413-80-3P**, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]benzoic acid Ethyl Ester **486414-92-0P**, 4-[[4-Amino-5-(2-fluorobenzoyl)thiazol-2-yl]amino]benzoic Acid Ethyl Ester **486414-93-1P**, 4-[[4-Amino-5-(2-fluorobenzoyl)thiazol-2-yl]amino]benzoic Acid **486415-05-8P**, 4-[[4-Amino-5-(2,6-difluoro-4-methylbenzoyl)thiazol-2-yl]amino]benzoic Acid **486415-07-0P**, 4-[[4-Amino-5-(2,6-difluoro-4-methylbenzoyl)thiazol-2-yl]amino]benzoic acid ethyl ester **486415-14-9P**, 4-[[4-Amino-5-(2-chloro-6-fluorobenzoyl)thiazol-2-yl]amino]benzoic Acid Ethyl Ester **486415-15-0P**, 4-[[4-Amino-5-(2-chloro-6-fluorobenzoyl)thiazol-2-yl]amino]benzoic Acid **486415-17-2P**, 4-[[5-(2-Acetylaminobenzoyl)-4-aminothiazol-2-yl]amino]benzoic Acid Ethyl Ester **486415-18-3P**, 4-[[5-(2-Acetylaminobenzoyl)-4-aminothiazol-2-yl]amino]benzoic Acid **486415-21-8P**, 4-[[4-Amino-5-(2-methanesulfonylbenzoyl)thiazol-2-yl]amino]benzoic Acid Ethyl Ester **486415-38-7P**, 4-[[4-Amino-5-(2,6-dichlorobenzoyl)thiazol-2-yl]amino]benzoic Acid tert-Butyl Ester **486415-45-6P**, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-2-chlorobenzoic acid **486415-47-8P**, 4-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]-2-hydroxybenzoic acid Phenyl Ester **486415-54-7P**, 3-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]benzoic acid tert-Butyl Ester **486415-55-8P**, 3-[[4-Amino-5-(2,6-difluorobenzoyl)thiazol-2-yl]amino]benzoic Acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolylamino benzamide derivs. as modulators of cell proliferation and inhibitors of protein kinases)

RN 223786-78-5 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(2,6-dichlorobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



RN 486413-80-3 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 486414-92-0 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(2-fluorobenzoyl)-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 486414-93-1 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(2-fluorobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



RN 486415-05-8 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(2,6-difluoro-4-methylbenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



RN 486415-07-0 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(2,6-difluoro-4-methylbenzoyl)-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 486415-14-9 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(2-chloro-6-fluorobenzoyl)-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 486415-15-0 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(2-chloro-6-fluorobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



RN 486415-17-2 HCAPLUS
CN Benzoic acid, 4-[[5-[2-(acetylamino)benzoyl]-4-amino-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 486415-18-3 HCAPLUS
CN Benzoic acid, 4-[[5-[2-(acetylamino)benzoyl]-4-amino-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



RN 486415-21-8 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-[2-(methylsulfonyl)benzoyl]-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 486415-38-7 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(2,6-dichlorobenzoyl)-2-thiazolyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 486415-45-6 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-2-chloro- (9CI) (CA INDEX NAME)



RN 486415-47-8 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-2-hydroxy-, phenyl ester (9CI) (CA INDEX NAME)



RN 486415-54-7 HCAPLUS
CN Benzoic acid, 3-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 486415-55-8 HCAPLUS
CN Benzoic acid, 3-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



L10 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:836322 HCAPLUS
DOCUMENT NUMBER: 134:162958
TITLE: A novel solid-phase approach to 2,4-diaminothiazoles

AUTHOR(S): Baer, Roman; Masquelin, Thierry
CORPORATE SOURCE: Department of Chemical Technologies, F. Hoffmann-La Roche AG, Basel, 4070, Switz.
SOURCE: Journal of Combinatorial Chemistry (2001), 3(1), 16-19
CODEN: JCCHFF; ISSN: 1520-4766
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:162958
GI



I



II

AB A novel solid-phase synthesis of a 2,4-diaminothiazole library starting from a polymer-bound thiouronium salt is described. The synthetic strategy involves formation of polymer-bound thioureido-thiourea intermediates I (R = Ph, 3-NCC6H4, MeO2CC6H4, 3-MeOC6H4, 4-F3CC6H4, MeO2CCH2, etc.; Q = resin) which by treatment with α-bromo ketones R1COCH2Br (R1 = cyclohexyl, 4-MeOC6H4, 4-FC6H4, naphthyl, 4-BrC6H4, cyclopentyl, 2-pyridinyl, pentyl, etc.) undergoes S-alkylation, followed by a base-catalyzed intramol.-ring closure/cleavage to give 2,4-diaminothiazoles II. This strategy tolerates a wide range of functionality and protecting groups. The novel feature of our method is a polymer-supported auto-scavenging strategy, which provides a clean, high-yielding, and traceless synthesis to 2,4-diaminothiazoles.

IT **325144-15-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid-phase preparation of diaminothiazole library via cyclization of polymer-bound thioureido-thioureas with bromo ketones)

RN 325144-15-8 HCAPLUS
CN Benzoic acid, 3-[[4-amino-5-(2-chlorobenzoyl)-2-thiazolyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:297411 HCAPLUS
DOCUMENT NUMBER: 130:325142
TITLE: Preparation of 4-aminothiazole derivatives as inhibitors of cyclin-dependent kinases
INVENTOR(S): Chong, Wesley K. M.; Chu, Shao Song; Duvadie, Rohit R.; Li, Lin; Xiao, Wei; Yang, Yi
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9921845	A2	19990506	WO 1998-US22809		19981027
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2306082	AA	19990506	CA 1998-2306082		19981027
AU 9913664	A1	19990517	AU 1999-13664		19981027
AU 738792	B2	20010927			
TR 200001081	T2	20001023	TR 2000-200001081		19981027
EP 1056732	A2	20001206	EP 1998-957393		19981027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
SI 20324	C	20010228	SI 1998-20068		19981027
EE 200000289	A	20010615	EE 2000-200000289		19981027
BR 9815200	A	20011016	BR 1998-15200		19981027
EP 1215208	A2	20020619	EP 2002-1881		19981027
EP 1215208	A3	20020904			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
NZ 503788	A	20021126	NZ 1998-503788		19981027
US 6569878	B1	20030527	US 1998-179744		19981027
NZ 517419	A	20030829	NZ 1998-517419		19981027
JP 2004500304	T2	20040108	JP 2000-517957		19981027
RO 119463	B1	20041130	RO 2000-423		19981027
NO 2000001955	A	20000616	NO 2000-1955		20000414
LT 4855	B	20011126	LT 2000-33		20000414
HR 2000000222	A1	20010228	HR 2000-222		20000417
MX 200003812	A	20001113	MX 2000-3812		20000418
LV 12592	B	20010720	LV 2000-51		20000503
BG 104478	A	20010228	BG 2000-104478		20000526
BG 64195	B1	20040430			
US 2003220326	A1	20031127	US 2003-388851		20030313
PRIORITY APPLN. INFO.:			US 1997-63634P	P	19971027
			US 1997-63666P	P	19971028
			EP 1998-957393	A3	19981027
			NZ 1998-503788	A1	19981027
			US 1998-179744	A3	19981027
			WO 1998-US22809	W	19981027

OTHER SOURCE(S): MARPAT 130:325142

GI



I

AB Title compds. [I; wherein R1 is a (un)substituted group selected from: alkyl, alkenyl, alkoxyl, alc., carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl, etc.; R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R independently is a halogen, haloalkyl, C-alkyl, C-alkenyl, C-alkynyl, hydroxyl, C-alkoxyl, amino, nitro, thiol, thioether, imine, cyano, amido, phosphonato, phosphine, carboxyl, thiocarbonyl, sulfonyl, sulfonamide, ketone, aldehyde, ester, oxygen, carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl], a pharmaceutically acceptable salt, a prodrug, pharmaceutically active metabolite of title compound, or pharmaceutically acceptable salt thereof, are prepared as inhibitors of cyclin-dependent kinases (CDKs: CDK1, CDK2, CDK4, and CDK6) to the therapeutic or prophylactic use of pharmaceutical compns. containing such compds. and to methods of treating malignancies and other disorders by administering effective amts. of such compds. Thus, I (R1 = C6H5; R2 = 3-NO2C6H4) was prepared with 52% yield from cyanamide, isothiocyanate, and 2-bromo-3'-nitroacetophenone in the presence of sodium.

IT **223783-73-1P 223783-85-5P 223784-44-9P**
223785-39-5P 223786-67-2P 223786-68-3P
223786-69-4P 223786-78-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of 4-aminothiazoles as inhibitors of cyclin-dependent kinases)

RN 223783-73-1 HCAPLUS

CN Benzoic acid, 4-[[4-amino-5-(2-nitrobenzoyl)-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 223783-85-5 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(4-methoxybenzoyl)-2-thiazolyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 223784-44-9 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(2,6-dichlorobenzoyl)-2-thiazolyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 223785-39-5 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(2-nitrobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



RN 223786-67-2 HCAPLUS
CN Benzoic acid, 3-[[4-amino-5-(3-methoxybenzoyl)-2-thiazolyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 223786-68-3 HCAPLUS
CN Benzoic acid, 3-[[4-amino-5-(4-bromobenzoyl)-2-thiazolyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 223786-69-4 HCAPLUS
CN Benzoic acid, 3-[[4-amino-5-(2-naphthalenylcarbonyl)-2-thiazolyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 223786-78-5 HCAPLUS
CN Benzoic acid, 4-[[4-amino-5-(2,6-dichlorobenzoyl)-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



=>